QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction

Core Insights - The company reported a 25% year-over-year revenue increase, reaching $2,676,074 for the year ended December 31, 2025, compared to $2,131,926 in 2024 [2] - Gross profit for 2025 was $1,795,182, reflecting over 32% growth year-over-year, with gross profit margin expanding from approximately 64% in 2024 to about 67% in 2025 [2][3] - The company successfully eliminated nearly all convertible debt, reducing it from approximately $2.0 million to about $20,000, which significantly strengthened its balance sheet [3] - Annual interest expense is expected to decline by over $200,000, enhancing cash flow and allowing for reinvestment in product development and platform expansion [4] - The company is experiencing growing momentum in its Integrated Service Program (ISP) client base, with early results from the Q-Cog pilot program indicating promising reimbursement activity [6] - Q-Cog is designed to meet CMS screening guidelines and supports cognitive and behavioral health screening, addressing a significant unmet need in primary care [7] - The combination of accelerating revenue growth, expanding margins, and a de-risked balance sheet positions the company well for continued progress in 2026 [8]